Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trial

• Published in: American journal of hematology Vol. 98; no. 7; pp. E168 - E171
• Main Authors: Makras, Polyzois, Yavropoulou, Maria P., Chatziioannou, Sofia N., Anastasilakis, Athanasios D., Georgakopoulou, Danai, Tsoli, Marina, Chatzelis, Eleftherios, Kaltsas, Gregory
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.07.2023; Wiley Subscription Services, Inc
• Subjects: Adult; Denosumab - therapeutic use; Hematology; Histiocytosis; Histiocytosis, Langerhans-Cell - drug therapy; Humans; Langerhans cell histiocytosis; Patients; Prospective Studies; Treatment Outcome

This phase IIb clinical trial evaluated the efficacy of a bimonthly treatment schedule (Q8W) with 4 subcutaneous doses of denosumab 120 mg among adults with Langerhans cell histiocytosis needing first‐line systemic therapy for either multifocal single‐system disease or multisystem disease without ri...